Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients

Clinical and Experimental Nephrology

Volumn 15, Issue 6, 2011, Pages 893-899

  Shiohira, Shunji ^a,d   Yoshida, Takumi ^a,b   Sugiura, Hidekazu ^a   Yoshida, Satsuki ^a   Mitobe, Michihiro ^a   Shimada, Katsunori ^c   Ohba, Takashi ^d   Tsuchiya, Ken ^a   Kabaya, Takashi ^d   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Yoshida Medical Clinic   (Japan)

^c STATZ Institute Inc   (Japan)

^d Minami Senju Hospital   (Japan)

Author keywords

Cilostazol; Peripheral artery disease; Restless legs syndrome

Indexed keywords

CILOSTAZOL; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOOT PAIN; HEART PALPITATION; HEMODIALYSIS PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; QUESTIONNAIRE; RESTLESS LEGS SYNDROME; SCORING SYSTEM; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; JAPAN; LIPIDS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RENAL DIALYSIS; RESTLESS LEGS SYNDROME; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855263232     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0485-2     Document Type: Article

References (22)

1. A Lindner B Charra DJ Sherrard BH Scribner 1974 Accelerated atherosclerosis in prolonged maintenance hemodialysis N Engl J Med 290 697 701 4813742 1:STN:280:DyaE2c7gtlGiuw%3D%3D
2. DJ Goldsmith A Covic 2001 Coronary artery disease in uremia: etiology, diagnosis, and therapy Kidney Int 60 2059 2078 11737581 1:STN:280: DC%2BD3MnovFyitg%3D%3D (Pubitemid 33070450)
3. A O'Hare K Johansen 2001 Lower-extremity peripheral arterial disease among patients with end-stage renal disease J Am Soc Nephrol 12 2838 2847 11729255 (Pubitemid 33115433)
4. B Phillips T Young L Finn K Asher WA Hening C Purvis 2000 Epidemiology of restless legs symptoms in adults Arch Intern Med 160 2137 2141 10904456 1:STN:280:DC%2BD3czptVKnsA%3D%3D (Pubitemid 30482720)
5. HG Beebe DL Dawson BS Cutler JA Herd DE Strandness Jr EB Bortey, et al. 1999 A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial Arch Intern Med 159 2041 2050 10510990 1:CAS:528:DyaK1MXms12mtr0%3D (Pubitemid 29453592)
6. AS Walters C LeBrocq A Dhar 2003 Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome Sleep Med 4 121 132 14592342 (Pubitemid 36527232)
7. M Yoshio T Tatsuzou Y Yoshihide K Sakuzou K Teruhisa W Masahiko, et al. 1986 Clinical evaluation of OPC-13013, a new platelet aggregation inhibitor, or chronic arterial occlusive diseases: dose finding study by double-blind method Clin Eval 14 13 41
8. M Notohamiprodjo K Andrassy J Bommer E Ritz 1986 Dialysis membranes and coagulation system Blood Purif 4 130 141 2942155 1:CAS:528:DyaL28XksFyrt7Y%3D (Pubitemid 16079377)
9. S Takahashi K Oida R Fujiwara H Maeda S Hayashi H Takai, et al. 1992 Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture J Cardiovasc Pharmacol 20 900 906 1282592 1:CAS:528:DyaK3sXlt1Wmsg%3D%3D (Pubitemid 23001455)
10. K Takei K Tokuyama M Kato A Morikawa 1998 Role of cyclic adenosine monophosphate in reducing superoxide anion generation in guinea pig alveolar macrophages Pharmacology 57 1 7 9670206 1:CAS:528:DyaK1cXktlKisbc%3D (Pubitemid 28288862)
11. S Hayashi R Morishita H Matsushita H Nakagami Y Taniyama T Nakamura, et al. 2000 Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21 Hypertension 35 237 243 10642304 1:CAS:528:DC%2BD3cXpt1aisg%3D%3D (Pubitemid 30054179)
12. M Aoki R Morishita H Matsushita S Hayashi H Nakagami K Yamamoto, et al. 1999 Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells. Potential role of p53 in regulation of vascular smooth muscle cell Hypertension 34 2 192 200 10454440 1:CAS:528:DyaK1MXlvFGmtLk%3D (Pubitemid 29409214)
13. M Aoki R Morishita S Hayashi N Jo K Matsumoto T Nakamura, et al. 2001 Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model Diabetologia 44 1034 1042 11484082 1:CAS:528:DC%2BD3MXlsFCgsbw%3D (Pubitemid 32778137)
14. T Inoue T Uchida M Sakuma Y Imoto Y Ozeki Y Ozaki, et al. 2004 Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation J Am Coll Cardiol 44 1408 1414 15464320 1:CAS:528:DC%2BD2cXot1WqtL4%3D (Pubitemid 39303941)
15. EO Mark AB Stephen AS Mohammed SY Ian L Bernard VS Chee 2009 The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease J Vasc Surg 49 5 1226 1234
16. N Zhang N Miyamoto R Tanaka H Mochizuki N Hattori T Urabe 2009 Activation of tyrosine hydroxylase prevents pneumonia in a rat chronic cerebral hypoperfusion model Neuroscience 158 665 672 19032975 1:CAS:528: DC%2BD1MXns12jtA%3D%3D
17. Y Brendon K Roo W Keith 2009 Restless legs syndrome Aust Fam Physician 38 5 296 300
18. V Collado-Seidel R Kohnen W Samtleben GF Hillebrand WH Oertel C Trenkwalder 1998 Clinical and biochemical findings in uremic patients with and without restless legs syndrome Am J Kidney Dis 31 2 324 328 9469505 1:STN:280:DyaK1c7ivFCjtQ%3D%3D (Pubitemid 28106426)
19. RL Muri 2009 Peripheral arterial disease: Pathophysiology, risk factors, diagnosis, treatment, and prevention J Vasc Nurs 27 2 26 30
20. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized, double-blind, pilot study. Lancet Neurol. 2008;7:494-9.
21. SW Park CW Lee HS Kim NH Lee DY Nah MK Hong, et al. 2000 Effects of cilostazol on angiographic restenosis after coronary stent replacement Am J Cardiol 86 499 503 11009265 1:CAS:528:DC%2BD3cXlvV2ku78%3D
22. SU Kwon YJ Cho JS Koo HJ Bae YS Lee KS Hong, et al. 2005 Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis Stroke 36 782 786 15746463 1:CAS:528: DC%2BD2MXislait7Y%3D